“Using big data and artificial intelligence algorithms…the biotech firm aims to isolate the root causes of many diseases, including cancer, and develop tailor-made treatment options for patients.”
Finding a cure for pancreatic cancer just got a healthy shot in the arm.
Berg, a small Boston-based biotech firm, is teaming up with an array of prestigious hospitals and research teams to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer, according to people with knowledge of the partnership.
Pancreatic cancer is one of the deadliest forms of the disease, with an average five-year survival rate of 7%. The partnership, which includes the Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, as well as the Pancreatic Cancer Research Team (PCRT), is scheduled to be announced on Tuesday.
Such a partnership is noteworthy because curing pancreatic and other aggressive types of cancers aren’t at the top of Big Pharma’s to-do list. That’s because finding a cure for cancer is, well, really hard. Instead, large pharmaceutical companies tend to focus their…
View original post 334 more words